tetano
Editor, Senior Moderator
Transpl Infect Dis. 2010 Nov 10. doi: 10.1111/j.1399-3062.2010.00582.x. [Epub ahead of print]
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
Renaud C, Pergam SA, Polyak C, Jain R, Kuypers J, Englund JA, Corey L, Boeckh MJ.
D?partement de Microbiologie et Immunologie, Centre Hospitalier Universitaire Sainte-Justine, Montr?al, Quebec, Canada Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA School of Pharmacy, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA.
Abstract
C. Renaud, S.A. Pergam, C. Polyak, R. Jain, J. Kuypers, J.A. Englund, L. Corey, M.J. Boeckh. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010. All rights reserved Abstract: Oseltamivir resistance in pandemic 2009 influenza A/H1N1 is caused by the neuraminidase mutation H275Y. This mutation has also been associated with in vitro resistance to peramivir, but few clinical cases have been described to date. Using allele-specific real-time reverse transcriptase polymerase chain reaction assay for the H275Y mutation, we were able to identify resistant H1N1 in a hematopoietic cell transplant recipient receiving intravenous peramivir therapy, and through serial testing we determined the molecular evolution of resistance. This case demonstrates that an H275Y mutant population can emerge early and replicate in vivo under peramivir antiviral pressure to become the major viral population.
? 2010 John Wiley & Sons A/S.
PMID: 21062390 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21062390
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
Renaud C, Pergam SA, Polyak C, Jain R, Kuypers J, Englund JA, Corey L, Boeckh MJ.
D?partement de Microbiologie et Immunologie, Centre Hospitalier Universitaire Sainte-Justine, Montr?al, Quebec, Canada Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA School of Pharmacy, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA.
Abstract
C. Renaud, S.A. Pergam, C. Polyak, R. Jain, J. Kuypers, J.A. Englund, L. Corey, M.J. Boeckh. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010. All rights reserved Abstract: Oseltamivir resistance in pandemic 2009 influenza A/H1N1 is caused by the neuraminidase mutation H275Y. This mutation has also been associated with in vitro resistance to peramivir, but few clinical cases have been described to date. Using allele-specific real-time reverse transcriptase polymerase chain reaction assay for the H275Y mutation, we were able to identify resistant H1N1 in a hematopoietic cell transplant recipient receiving intravenous peramivir therapy, and through serial testing we determined the molecular evolution of resistance. This case demonstrates that an H275Y mutant population can emerge early and replicate in vivo under peramivir antiviral pressure to become the major viral population.
? 2010 John Wiley & Sons A/S.
PMID: 21062390 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21062390